 The study found that perioperative enacetylcysteine, NAC, administration did not significantly reduce the risk of cardiac surgery associated acute kidney injury, CSA-AKI, in adults undergoing elective cardiac surgery, as evidenced by similar rates of CSA-AKI occurrence, change in creatinine levels, and in-hospital mortality between NAC-treated and placebo groups. This article was authored by Mai Mai, Hong Wen Zhao, Chen Guang Pan, and others.